secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-115119
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission
--------------------------------------------------------------------------------

- Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
- Full-year 2025 net loss $165.7M ($2.27/sh) vs $80.6M ($1.32/sh) in 2024.
- Cash & equivalents $136.9M at Dec 31, 2025; pro forma $244.5M after Feb 2026 $107.6M offering, runway into Q2 2027.
- FDA granted Breakthrough Therapy Designation for nomlabofusp in FA; FDA alignment on FXN as surrogate endpoint.
- Phase 3 confirmatory study screening to start Q2 2026; topline open-label data expected Q2 2026; BLA submission June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/0001193125-26-115119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-115119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer